Disease · MONDO_0004985
Comparisons in its trials135
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 135
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lumateperone 42mg vs Placebo: deaths from any cause | 0 of 240 | 0 of 241 | 481 | NCT04285515 | Trial comparisons |
| Lumateperone 42mg vs Placebo: serious adverse events | 0 of 240 | 1 of 241 | 481 | NCT04285515 | Trial comparisons |
| Iloperidone vs Placebo: deaths from any cause | 0 of 206 | 0 of 208 | 414 | NCT04819776 | Trial comparisons |
| Iloperidone vs Placebo: serious adverse events | 4 of 206 | 1 of 208 | 414 | NCT04819776 | Trial comparisons |
| Lumateperone vs Placebo: deaths from any cause | 0 of 188 | 0 of 189 | 377 | NCT03249376 | Trial comparisons |
| Lumateperone vs Placebo: serious adverse events | 1 of 188 | 0 of 189 | 377 | NCT03249376 | Trial comparisons |
| Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: Response Rate (Number of Patients With Clinically Response) | 139 of 187 | 153 of 189 | 376 | NCT00672490 | Trial comparisons |
| Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: Remission Rate (Number of Patients With Clinically Significant Remission) | 117 of 187 | 123 of 189 | 376 | NCT00672490 | Trial comparisons |
| Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: serious adverse events | 0 of 187 | 1 of 189 | 376 | NCT00672490 | Trial comparisons |
| Lithium+Quetiapine XR vs Placebo+Quetiapine XR: serious adverse events | 4 of 173 | 8 of 183 | 356 | NCT00931723 | Trial comparisons |
| Lithium+Quetiapine XR vs Placebo+Quetiapine XR: The Number of Patients With Clinically Significant Response. | 137 of 173 | 120 of 176 | 349 | NCT00931723 | Trial comparisons |
| Lithium+Quetiapine XR vs Placebo+Quetiapine XR: Remission | 125 of 173 | 105 of 176 | 349 | NCT00931723 | Trial comparisons |
| Lithium+Quetiapine XR vs Placebo+Quetiapine XR: Improvement of Overall Bipolar Illness | 134 of 173 | 125 of 176 | 349 | NCT00931723 | Trial comparisons |
| Luradisone vs Placebo: serious adverse events | 2 of 175 | 4 of 172 | 347 | NCT02046369 | Trial comparisons |
| QUETIAPINE XR vs PLACEBO: serious adverse events | 0 of 147 | 3 of 147 | 294 | NCT01256177 | Trial comparisons |
| OPT With Lithium vs OPT Without Lithium: serious adverse events | 14 of 141 | 12 of 142 | 283 | NCT00667745 | Trial comparisons |
| Quetiapine XR vs Placebo: The Proportion of Patients at Week 8 With a Clinical Global Impression - Bipolar - Change (CGI-BP-C) of Much or Very Much Improved | 91 of 139 | 65 of 140 | 279 | NCT01256177 | Trial comparisons |
| Quetiapine XR vs Placebo: Incidence of Treatment-emergent Mania (AE of Mania or Hypomania, Defined as Young Mania Rating Scale [YMRS] Score ≥16 on 2 Consecutive Assessments or Final Assessment) | 1 of 139 | 4 of 140 | 279 | NCT01256177 | Trial comparisons |
| Quetiapine XR vs Placebo: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment) | 88 of 139 | 59 of 140 | 279 | NCT01256177 | Trial comparisons |
| Quetiapine XR vs Placebo: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Response (Subjects With ≥50% Reduction From Baseline to Week 8 in MADRS Total Score) | 93 of 139 | 62 of 140 | 279 | NCT01256177 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004985/comparisons